Stockreport

Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF Bavarian Nordic and Bristol-Myers Squibb agree to supply clinical material for the trial Investigator-led study represents the fourth clinical combination of CV301 wit [Read more]